5-Aza-2'-deoxycytidine (d-AZA) inhibits methylation of DNA, a process that serves as an epigenetic regulator of gene expression. We have shown that d-AZA causes temporally related defects in mice. Gestational day (GD) 10 treatment induced severe long-bone defects of the hindlimb but not the forelimb
Teratogenic effects of the demethylating agent 5-aza-2′-deoxycytidine in the Swiss Webster mouse
✍ Scribed by Stacy Branch; Bettina M. Francis; Cecil F. Brownie; Neil Chernoff
- Publisher
- Elsevier Science
- Year
- 1996
- Tongue
- English
- Weight
- 723 KB
- Volume
- 112
- Category
- Article
- ISSN
- 0300-483X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract In gastric cancer, increasing numbers of genes have been reported to be silenced by aberrant methylation. However, global analysis of epigenetic inactivation in cancer cells has rarely been performed. For screening the genes upregulated by the demethylating agent 5‐aza‐2′‐deoxycytidine
## Abstract Cancer/testis antigens (CTAs) are considered to be suitable targets for the immunotherapy of human malignancies. It has been demonstrated that in a variety of tumors, the expression of certain CTAs is activated __via__ the demethylation of their promoter CpG islands. In our study, we ha
## Abstract Naturally occurring molecules with putative cancer chemopreventive properties such as the phytoalexin resveratrol (3,5,4′‐trihydroxystilbene) are lead molecules that guide the design of novel agents with improved pharmacologic properties. The synthetic resveratrol analog 3,4,5,4′‐tetram